Latest Breaking News On - நீரிழிவு கிட்நீ நோய் - Page 1 : comparemela.com

Jun 29 2021 DJS Antibodies has announced its move into over 2,000 sqft of newly converted class II laboratory and office space at The Oxford Trust’s Wood Centre for Innovation, the second biotech to join alongside recent occupant Samsara Therapeutics. Founded in 2015 by David Llewellyn and Joe Illingworth, who met at the University of Oxford’s Jenner Institute, DJS is working on therapeutics to treat critical inflammatory diseases that account for more than 50% of deaths worldwide. The lead programme of its HEPTAD antibody discovery platform targets a validated GPCR (G protein-coupled receptor) for the treatment of Diabetic Kidney Disease, a long-term condition that causes the irreversible loss of kidney function.

United kingdomSteve burgessDavid llewellynJoe illingworthOxford trust wood centre for innovationUniversity of oxford jenner instituteWood centreWood centre for innovationOxfordshire local enterprise partnership oxScience oxford centreGovernment local growth fundLoxford trustJenner instituteDiabetic kidney diseaseLocal growth fundOxfordshire local enterprise partnership